Please assess the completion status of the following clinical trial:

Trial Title: DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Has pathologically documented unresectable, recurrent, or metastatic colorectal adenocarcinoma (until sponsor's notification to the study sites, subject must be a RAS/BRAF wild-type cancer)~* Has received at least 2 prior regimens of standard treatment~* Has measurable disease assessed by the investigator based on RECIST version 1.1.~* Has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1~Exclusion Criteria:~* Has a medical history of myocardial infarction within 6 months, symptomatic congestive heart failure~* Has a medical history of clinically significant lung disease~* Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DS-8201a Cohort A (Type: EXPERIMENTAL): Cohort A is comprised of participants with HER2-positive (IHC 3+ or IHC 2+/ISH +) who will receive DS-8201a once every 3 weeks
- DS-8201a Cohort B (Type: EXPERIMENTAL): Cohort B is comprised of participants with HER2 IHC 2+/ISH - who will receive DS-8201a once every 3 weeks
- DS-8201a Cohort C (Type: EXPERIMENTAL): Cohort C is comprised of participants with HER2 IHC 1+ who will receive DS-8201a once every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).